Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Participants may be helping themselves, but it is expected that the information from this study may help doctors and scientists to improve treatment for people who have kidney disease. If empagliflozin is shown to have benefits, results from this study may help to prevent deaths from heart disease and the need for dialysis or transplantation around the world.

Please note that participants are donating their time, information and blood/urine samples, for which we are grateful, but they or their relatives will not be able to receive any financial benefits from any discoveries or products developed using the results from this study or any future research using their health information and data.